Trial Profile
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2018
Price :
$35
*
At a glance
- Drugs Nimodipine (Primary) ; Nimodipine
- Indications Cerebral ischaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms NEWTON
- Sponsors Edge Therapeutics
- 24 Feb 2017 Results presented at the 42nd International Stroke Conference
- 09 Dec 2016 According to an Edge Therapeutics media release, results of this trial are scheduled for print publication in the January 2017 issue of Stroke.
- 09 Dec 2016 Results published in the an Edge Therapeutics Media Release